GB1520200A - Antitumour vaccines and their preparation - Google Patents

Antitumour vaccines and their preparation

Info

Publication number
GB1520200A
GB1520200A GB53723/76A GB5372376A GB1520200A GB 1520200 A GB1520200 A GB 1520200A GB 53723/76 A GB53723/76 A GB 53723/76A GB 5372376 A GB5372376 A GB 5372376A GB 1520200 A GB1520200 A GB 1520200A
Authority
GB
United Kingdom
Prior art keywords
species
virus
mammal
oncolysate
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB53723/76A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of GB1520200A publication Critical patent/GB1520200A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB53723/76A 1976-06-01 1976-12-23 Antitumour vaccines and their preparation Expired GB1520200A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/691,486 US4108983A (en) 1976-06-01 1976-06-01 Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors

Publications (1)

Publication Number Publication Date
GB1520200A true GB1520200A (en) 1978-08-02

Family

ID=24776726

Family Applications (1)

Application Number Title Priority Date Filing Date
GB53723/76A Expired GB1520200A (en) 1976-06-01 1976-12-23 Antitumour vaccines and their preparation

Country Status (8)

Country Link
US (1) US4108983A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS52148617A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU511071B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1073814A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2705610A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2353641A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1520200A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ182891A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037441B1 (en) * 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
JPS5835121A (ja) * 1981-08-20 1983-03-01 ビラス・ヴィー・リクハイト 免疫刺激性補助剤からなる抗原及び免疫療法におけるその使用
US4652522A (en) * 1983-07-05 1987-03-24 The University Of Pennsylvania Continuous lymphocyte cell lines, their production and use
JPS6038328A (ja) * 1983-08-11 1985-02-27 Handai Biseibutsubiyou Kenkyukai 抗腫瘍免疫誘導の増強法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US6338853B1 (en) 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
WO1990011765A1 (en) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
ATE411809T1 (de) * 1993-04-30 2008-11-15 Wellstat Biologics Corp Zusuammensetzungen zur behandlung von krebs mittels viren
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
WO2000062735A2 (en) * 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6586411B1 (en) * 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1984007B1 (en) * 2006-02-13 2015-08-19 Oncolytics Biotech Inc. Use of low dose local immune suppression to enhance oncolytic viral therapy
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2012031137A2 (en) 2010-09-02 2012-03-08 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9623096B2 (en) 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553312A (en) * 1968-02-26 1971-01-05 Flow Lab Process for producing rubella-virus hemagglutinating antigen

Also Published As

Publication number Publication date
FR2353641A1 (fr) 1977-12-30
FR2353641B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1980-07-18
DE2705610C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-08-03
JPS52148617A (en) 1977-12-10
AU511071B2 (en) 1980-07-24
CA1073814A (en) 1980-03-18
DE2705610A1 (de) 1977-12-15
AU2173577A (en) 1978-08-03
NZ182891A (en) 1984-03-30
US4108983A (en) 1978-08-22

Similar Documents

Publication Publication Date Title
GB1520200A (en) Antitumour vaccines and their preparation
Heppner Studies on serum‐mediated inhibition of cellular immunity to spontaneous mouse mammary tumors
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
US3674864A (en) Process for stabilizing preparations of interfering viruses
GB2079786B (en) Production of viral antigens
Brunner et al. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.
GB1177635A (en) Cell Stains.
Hirst et al. A new method for concentrating influenza virus from allantoic fluid
ES373631A1 (es) Procedimiento para la obtencion de una vacuna activa contrala enfermedad de maret.
GB1486186A (en) Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection
Sato et al. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer
Takemoto et al. Influence of acid polysaccharides on plaque formation by influenza A2 and B viruses
IE40221B1 (en) Influenza vaccines
Damjanov et al. Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host
CN106978397A (zh) 一种人dc-cik免疫活性细胞及其制备方法
US3418210A (en) Hamster ascites tumor cell line bhk 21/c.13/t.6/ascites useful in submerged serum-free agar cultures to support virus growth
ATE86308T1 (de) Menschlicher b-lymphotroper virus (hblv), isolierung und erzeugnisse.
GB1358321A (en) Method od tissue cell culture
GB1135987A (en) Attenuated live rubella virus vaccine and method of production
GB1453035A (en) Virus vaccine production
Ramoni et al. Expression of Viral and/or Hemoglobin Antigens in
ES8107300A1 (es) Un metodo para la preparacion de una composicion de virus herpes
Clark et al. Sv40‐induced transformation of cells of the lizard Gekko gecko
Abramoff et al. Cytotoxicity of heterologous immune chicken serum to normal and neoplastic mouse tissues in culture

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee